再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

盘后交易 12-05 17:44:23 EST

19.50

-0.45

-2.26%

盘后19.55

+0.05+0.26%

17:20 EST

最高20.22	最低19.40	成交量101.94万
今开20.15	昨收19.95	日振幅4.11%
总市值21.70亿	流通市值21.33亿	总股本1.11亿
成交额1,997万	换手率0.93%	流通股本1.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":19.5,"timestamp":1764968400000,"preClose":19.95,"halted":0,"volume":1019406,"hourTrading":{"tag":"盘后","latestPrice":19.55,"preClose":19.5,"latestTime":"17:20 EST","volume":14321,"amount":279275.940508,"timestamp":1764973250940},"delay":0,"floatShares":109371942,"shares":111270801,"eps":-1.922867,"marketStatus":"盘后交易","change":-0.45,"latestTime":"12-05 17:44:23 EST","open":20.15,"high":20.22,"low":19.4,"amount":19965472.233588003,"amplitude":0.041103,"askPrice":20,"askSize":26,"bidPrice":19.5,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.922867,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1764982800000},"marketStatusCode":4,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":19.95,"preHourTrading":{"tag":"盘前","latestPrice":20.1689,"preClose":19.95,"latestTime":"08:57 EST","volume":76,"amount":1532.827508,"timestamp":1764943036712},"postHourTrading":{"tag":"盘后","latestPrice":19.55,"preClose":19.5,"latestTime":"17:20 EST","volume":14321,"amount":279275.940508,"timestamp":1764973250940},"volumeRatio":1.646459,"impliedVol":0.5611,"impliedVolPercentile":0.24},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2588082048","title":"再鼎医药(09688)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2588082048","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588082048?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:36","pubTimestamp":1764761787,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年12月1日(美国东部时间)，本公司根据2024年股权激励计划向3名承授人授出可认购合共11,800股美国存托股份的购股权并向6名承授人涉及合共22,665股美国存托股份的受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1574","BK4139","BK1588","BK4531","BK4588","09688","BK4548","LU2488822045.USD","BK4526","BK1161","ZLAB"],"gpt_icon":0},{"id":"2584945044","title":"再鼎医药(09688)根据股权激励计划发行200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584945044","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584945044?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:13","pubTimestamp":1763554404,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年11月19日，该公司发行200万股新股，由受托人持有，以兑现按先前披露的条款(1)归属根据 2017，2022及2024年股权激励计划所授出的股份奖励，及(2)如适用，行使根据2015，2017，2022及2024年股权激励计划所授出的期权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4548","ZLAB","BK4531","LU2488822045.USD","BK1588","BK4139","BK4585","BK1161","BK4588","09688","BK4526","BK1574"],"gpt_icon":0},{"id":"2584295603","title":"热门中概股悉数下跌 纳斯达克中国金龙指数跌1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584295603","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584295603?lang=zh_cn&edition=full","pubTime":"2025-11-18 23:11","pubTimestamp":1763478667,"startTime":"0","endTime":"0","summary":"金吾财讯 | 热门中概股悉数下跌，纳斯达克中国金龙指数跌1.07%。BOSS直聘(BZ)跌5.51%，拼多多(PDD)跌5.39%，瑞幸咖啡(LKNCY)跌4.38%，亚朵(ATAT)跌4.17%，禾赛(HSAI)跌3.55%，再鼎医药(ZLAB)跌2.87%，腾讯音乐(TME)跌2.75%，蔚来(NIO)跌2.94%，万国数据(GDS)跌2.49%。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/ZGIxNTcwOGM2NDcyYjg1YTQwZGM4YzE1NmM3NzkzMzkxMDg4NTA3.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZGIxNTcwOGM2NDcyYjg1YTQwZGM4YzE1NmM3NzkzMzkxMDg4NTA3.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"294574","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0683595622.HKD","LU1880383366.USD","LU0871576103.HKD","IE0034224299.USD","BK4108","LU0456842615.SGD","LU0561508036.HKD","LU1048588211.SGD","LU1719994722.HKD","LU1868837565.USD","09866","BK4532","LU0052750758.USD","LU1794554557.SGD","LU2039709279.SGD","BZ","NIO","TME","GDS","01698","PDD","EVS.SI","BK4501","LU0594300419.USD","LU0823426308.USD","HK0000320264.USD","BK4503","TTTN","LU0516422952.EUR","LU0329678170.USD","LU0359202008.SGD","LU2087589342.USD","LU0235996351.USD","LKNCY","BK4553","LU0456846285.SGD","BK4531","LU0516422440.USD","ATAT","NIO.SI","LU0307460666.USD","HSAI","SG9999011746.SGD","ZLAB","LU0633140727.USD","BK4534","LU0823038988.USD","LU0516422366.SGD","LU0143863784.USD","BK4563"],"gpt_icon":0},{"id":"2582351030","title":"再鼎医药(09688)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2582351030","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582351030?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:16","pubTimestamp":1762852561,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年11月10日(美国东部时间)，公司根据2024年股权激励计划向1名承授人授出可认购合共500股美国存托股份的购股权并向78名承授人涉及合共7.21万股美国存托股份的受限制股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","09688","BK4526","BK4585","ZLAB","BK1588","LU2488822045.USD","BK1161","BK4531","BK4548","BK4139","BK1574"],"gpt_icon":0},{"id":"2582435357","title":"【券商聚焦】浦银国际维持再鼎医药(ZLAB/09688)“买入”评级 指核心管线Zoci未来12个月催化剂丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2582435357","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582435357?lang=zh_cn&edition=full","pubTime":"2025-11-11 15:29","pubTimestamp":1762846196,"startTime":"0","endTime":"0","summary":"3Q25产品毛利率为59.5%，仍然延续2Q25以来同比环比均下降的趋势。基于此，以及考虑到四季度因医保谈判带来的渠道补偿，该机构预计四季度艾加莫德销售增速或较为温和。重点关注全球管线资产研发进展，其中核心管线Zoci未来12个月催化剂丰富，包括2L+SCLC1期颅内疗效数据更新、1LSCLC联用1期数据、NEC1期数据均有望于1H26读出，且公司预计Zoci+PDL1±chemo注册临床及NEC具备注册潜力的队列有望于2026年开启。此外，公司亦有望于2026年开展更多Zoci与新型疗法的联用1期试验。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969424","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"1190254329","title":"异动解读 | 再鼎医药盘中大跌5.05%，三季度业绩未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1190254329","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190254329?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:38","pubTimestamp":1762526296,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大跌5.05%，引发市场关注。这一跌幅主要与公司近期发布的第三季度财报有关。根据再鼎医药公布的2025年第三季度业绩报告，公司总收入为1.16亿美元，同比增长14%。值得注意的是，再鼎医药将2025年全年总收入指引调整为至少4.6亿美元。这一调整可能被市场解读为公司对未来业绩预期的下调，进一步加剧了投资者的忧虑情绪。在生物科技股整体走弱的背景下，再鼎医药的股价承压下行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZLAB"],"gpt_icon":0},{"id":"2581091628","title":"再鼎医药(09688)第三季度总收入同比增长14%，达1.161亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091628","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581091628?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:17","pubTimestamp":1762438643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药 公布2025年第三季度业绩，总收入同比增长14%，达1.161亿美元;经营亏损为4880万美元，同比收窄28%，调整后的经营亏损收窄42%至2,800万美元;调整2025年全年总收入指引为至少4.60亿美元。其中，产品收入净额为1.154亿美元，2024年同期为1.018亿美元，同比增长 13%，按固定汇率计算同比增长14%。这一增长主要是由纽再乐和鼎优乐销售额增长所驱动，部分被则乐销量放缓所抵销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药(09688)第三季度总收入同比增长14%，达1.161亿美元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK4526","BK4531","BK1574","BK4548","BK4585","ZLAB","BK4588","BK1588","BK4139","LU2488822045.USD","09688"],"gpt_icon":1},{"id":"2581797592","title":"再鼎医药胃癌新药临床研究因疗效不足终止，相关研发进程受影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2581797592","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581797592?lang=zh_cn&edition=full","pubTime":"2025-11-05 09:23","pubTimestamp":1762305780,"startTime":"0","endTime":"0","summary":"11月5日，再鼎医药（09688/ZLAB）发布公告，公司的合作伙伴安进公司于2025年11月4日宣布，关于贝玛妥珠单抗联合化疗及纳武利尤单抗用于一线胃癌的1b/3期临床研究FORTITUDE-102，由于临时分析显示疗效不足，该研究已被停止。此决定是基于资料监查委员会的要求。公司表示将继续与安进公司密切合作，并在适当时提供进一步的更新。此次研究的停止将影响公司的相关研发进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511053555495121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4526","BK4531","BK1574","BK4548","BK4585","ZLAB","BK4588","BK1588","BK4139","LU2488822045.USD","09688"],"gpt_icon":0},{"id":"2581944767","title":"再鼎医药(09688)：关于安进公司贝玛妥珠单抗 1b/3期临床研究FORTITUDE-102的更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2581944767","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581944767?lang=zh_cn&edition=full","pubTime":"2025-11-05 08:04","pubTimestamp":1762301064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司的合作伙伴及该研究申办方安进公司，于2025年11月4日在其2025年第三季度财报发布会期间宣布，评估贝玛妥珠单抗联合化疗及纳武利尤单抗用于一线胃癌的 1b/3 期临床研究FORTITUDE-102，由于根据资料监查委员会的要求所做的临时分析显示疗效不足已停止。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00BJJMRZ35.SGD","LU0889565916.HKD","LU1061106388.HKD","LU1571399168.USD","SG9999001440.SGD","BK4585","LU0109394709.USD","LU2488822045.USD","IE00BFTCPJ56.SGD","09688","BK4599","LU2089984988.USD","BK4526","LU2468319806.SGD","IE00B2B36J28.USD","LU1023059063.AUD","BK4533","BK4139","LU0058720904.USD","LU1983299246.USD","LU2242652126.USD","LU0289739699.SGD","IE0009355771.USD","LU0122379950.USD","IE00BJT1NW94.SGD","BK1161","LU2242646821.SGD","AMGN","IE0002141913.USD","BK4566","LU0868494617.USD","BK4548","BK4534","BK4588","BK4531","IE00B4R5TH58.HKD","BK1588","BK4581","LU1057294990.SGD","LU0320765992.SGD","LU2112291526.USD","BK1574","ZLAB"],"gpt_icon":0},{"id":"2579633461","title":"摩根大通增持再鼎医药(09688)约61.11万股 每股作价约20.56港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579633461","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579633461?lang=zh_cn&edition=full","pubTime":"2025-10-31 20:12","pubTimestamp":1761912756,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，10月27日，摩根大通增持再鼎医药(09688)61.1105万股，每股作价20.5592港元，总金额约为1256.38万港元。增持后最新持股数目约为1.23亿股，最新持股比例为11.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"摩根大通增持再鼎医药(09688)约61.11万股 每股作价约20.56港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2023250504.SGD","LU2023250843.SGD","LU0265550359.USD","SG9999002232.USD","LU0149725797.USD","LU1363072403.SGD","LU2462157665.USD","LU1720051017.SGD","IE00BJTD4N35.SGD","BK4550","LU0496365809.HKD","LU2417539215.USD","LU0689472784.USD","LU1244550221.USD","09688","LU1670628061.USD","LU2430703251.USD","LU1894683348.USD","LU0882574139.USD","LU2237443549.SGD","LU0211327993.USD","LU2237443622.USD","IE00BZ1G4Q59.USD","IE00BLSP4452.SGD","LU1244550494.USD","BK4548","BK4585","IE00BYXW3230.USD","LU0265550946.USD","LU1551013425.SGD","LU0964807845.USD","LU1974910355.USD","LU0868494617.USD","LU2211815571.USD","ZLAB","LU2242649171.HKD","LU1280957306.USD","LU2237443382.USD","SG9999002224.SGD","BK4588","LU2213496289.HKD","LU0976567544.SGD","LU2746668974.SGD","LU0320765489.SGD","LU0417517546.SGD","IE0034235188.USD","LU2023250330.USD","LU2237443895.HKD","LU2756315318.SGD","LU0971096721.USD"],"gpt_icon":0},{"id":"2579970521","title":"再鼎医药盘前涨超2.8%，获瑞银给予“买入”评级+近期催化剂明确","url":"https://stock-news.laohu8.com/highlight/detail?id=2579970521","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579970521?lang=zh_cn&edition=full","pubTime":"2025-10-30 16:28","pubTimestamp":1761812889,"startTime":"0","endTime":"0","summary":"再鼎医药(ZLAB.US)盘前涨超2.8%，报26.05美元。消息面上，瑞银近日发表研报，首次覆盖再鼎医药，给予“买入”评级，基于现金流折现法(DCF)对其目标价为33.5港元。瑞银预期集团核心产品VYVGART将持续扩展适应症并提升销售额，同时预期数个重磅候选药物产品将获批；认为ZL-1310(DLL3ADC)及ZL-1503(IL-13/IL-31R)的业务发展(BD)机会，将为近期增长动力；并相信市场似乎忽略了集团短期增长及业务发展潜力。\n\n美股频道更多独家策划、专家专栏，免费查阅>>\n\r\n            责任编辑：山上","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2025/10/30162853915080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["ZLAB","09688"],"gpt_icon":0},{"id":"2578699178","title":"瑞银：首予再鼎医药(09688)“买入”评级 近期具明确催化剂但被低估","url":"https://stock-news.laohu8.com/highlight/detail?id=2578699178","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578699178?lang=zh_cn&edition=full","pubTime":"2025-10-27 13:48","pubTimestamp":1761544080,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，基于现金流折现法，对再鼎医药目标价为33.5港元，分别意味着1倍、1.6倍未调整/调整后价格对高峰销售。瑞银认为，市场似乎忽略了再鼎医药的短期增长潜力，包括VYVGART及新产品推出，以及DLL3ADC及ZL-1503等产品的业务发展潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ZLAB","09688"],"gpt_icon":0},{"id":"2578526897","title":"再鼎医药公布Zocilurtatug Pelitecan（前称ZL-1310）最新一期临床数据， 显示其成为同类首创用于小细胞肺癌的靶向DLL3 ADC的潜力，并启动全球三期注册研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2578526897","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578526897?lang=zh_cn&edition=full","pubTime":"2025-10-25 00:10","pubTimestamp":1761322200,"startTime":"0","endTime":"0","summary":"有11例患者曾接受过DLL3双特异性抗体治疗。共有5例患者因治疗相关不良事件终止治疗，均发生于较高的剂量组。鉴于小细胞肺癌侵袭性强、治疗选择有限，临床对新疗法存在迫切需求。Zoci最新的1期研究结果显示，在患者尤其是是伴有不良预后因素的患者中，显示出快速且持续的缓解，这进一步为其作为潜在的差异化靶向DLL3 ADC提供了最新临床证据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4806457_ZH06457_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4585","BK1574","ZLAB","BK4139","BK1588","BK4080","BK4531","BK4588","09688","BK4231","BK4548","LU2488822045.USD","BK4526","BK1161","ADC"],"gpt_icon":0},{"id":"2577309302","title":"再鼎医药(09688.HK)拟11月6日举行董事会会议审批第三季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2577309302","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577309302?lang=zh_cn&edition=full","pubTime":"2025-10-23 20:47","pubTimestamp":1761223625,"startTime":"0","endTime":"0","summary":"格隆汇10月23日丨再鼎医药(09688.HK)公告，董事会审核委员会将于2025年11月6日(星期四)审议及批准(其中包括)根据美国公认会计准则及美国证券交易委员会的适用规则编制的公司及其附属公司截至2025年9月30日止三个月和九个月的未经审核季度业绩(第三季度业绩)及其发布。\r\n\r\n　　\r\n\r\n　　【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251023/31731691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4585","09688","ZLAB","BK1588","BK4548","BK4588","BK4139","BK4531","LU2488822045.USD","BK4526","BK1574","BK1161"],"gpt_icon":0},{"id":"2572519244","title":"再鼎医药(09688)授出购股权和受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2572519244","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572519244?lang=zh_cn&edition=full","pubTime":"2025-10-02 19:12","pubTimestamp":1759403553,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年10月1日(美国东部时间)，公司根据2024年股权激励计划向1名承授人授出可认购合共2.5万股美国存托股份的购股权并向7名承授人涉及合共3.22万股美国存托股份的受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1351960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4548","LU2488822045.USD","BK4139","09688","BK1574","BK4526","BK1588","BK4531","BK1161","BK4585","BK4588","ZLAB"],"gpt_icon":0},{"id":"2571326908","title":"美股异动 | 再鼎医药(ZLAB.US)涨逾4%  机构：药品关税对产业链影响有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2571326908","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571326908?lang=zh_cn&edition=full","pubTime":"2025-09-30 22:12","pubTimestamp":1759241543,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，再鼎医药涨逾4%，报34.43美元。消息面上，特朗普近期宣布，10月起对所有品牌/专利药征收100%关税，除非该制造商正在美国境内兴建生产设施。交银国际认为，这对中国创新药产业链影响有限，无需过度担忧。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1351558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4526","BK4531","BK1574","BK4548","BK4585","ZLAB","BK4588","BK1588","BK4139","LU2488822045.USD","09688"],"gpt_icon":0},{"id":"2571395433","title":"港股生物医药板块活跃，再鼎医药涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571395433","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571395433?lang=zh_cn&edition=full","pubTime":"2025-09-30 10:02","pubTimestamp":1759197721,"startTime":"0","endTime":"0","summary":"每经AI快讯，9月30日，港股生物医药板块活跃，再鼎医药涨超5%，药明康德、荣昌生物、诺诚健华等个股跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202509303527247688.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509303527247688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4548","LU2488822045.USD","YANG","BK4139","09688","BK1574","BK4526","BK1588","BK4531","BK1161","BK4585","BK4588","ZLAB","HSTECH","BK4614","HSCEI"],"gpt_icon":0},{"id":"2569095723","title":"申万宏源：首予再鼎医药(09688)“买入”评级 目标价35.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569095723","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569095723?lang=zh_cn&edition=full","pubTime":"2025-09-24 09:13","pubTimestamp":1758676413,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，申万宏源发布研报称，随着商业化产品的销售放量，以及本地化生产布局，再鼎医药预计将于2025年四季度实现non-GAAP经营利润。基于DCF模型，给予目标价35.2港元。目标价对应39%的上涨空间，看好公司的创新管线布局，首次覆盖给予买入评级。2024年艾加莫德国内销售额达到0.94亿美元，同比增长835%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1348740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","ZLAB","000166"],"gpt_icon":0},{"id":"2567796181","title":"耐心持有！东方红资产管理江琦：创新药是基本面推动的长周期行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2567796181","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567796181?lang=zh_cn&edition=full","pubTime":"2025-09-13 16:41","pubTimestamp":1757752871,"startTime":"0","endTime":"0","summary":"江琦从2024年初就明确表示，创新药是未来增速最快的医药子行业，并在2024年三季度将较多仓位集中于创新药。未来中国创新药将迎来从1到10的爆发阶段 江琦表示，2025年是创新药在资本市场的开花结果之年。江琦称，创新药行业已历经十年发展。江琦认为，创新药的魅力恰恰在于其从利润很小到利润很高的成长过程，这个生命周期通常以十年为单位。底部深耕，耐心持有 站在当下，江琦对创新药未来中长期的表现充满信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250913164111952aafc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250913164111952aafc4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","09983","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0634319403.HKD","BK1574","LU0348784397.USD","LU2778985437.USD","01801","09969","01276","LU0348783233.USD","LU0417516902.SGD","01877","LU0348766576.USD","IE00B543WZ88.USD","LU0348735423.USD","BK1229","LU0348827113.USD","LU1794554557.SGD","LU0540923850.HKD","LU0348825331.USD","ZLAB","BK1258","LU1720050803.USD","06978","LU0561508036.HKD","BK1161","09995","LU0417516738.SGD","BK1583","LU2476274720.SGD","09926","BK1542","LU0348767384.USD","IE00BPRC5H50.USD","LU2476274308.USD"],"gpt_icon":0},{"id":"2566928850","title":"港股异动 | 医药股多数反弹 创新药再迎利好 多家药企称海外传闻不影响出海预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2566928850","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566928850?lang=zh_cn&edition=full","pubTime":"2025-09-12 13:44","pubTimestamp":1757655876,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","LU1794554557.SGD","00013","HCM","BK4531","LU0348766576.USD","LU0540923850.HKD","09939","BK4007","688428","159938","09969","LU0348825331.USD","09688","BK1587","LU0348735423.USD","BK4588","IE00BPRC5H50.USD","06978","09926","LU2488822045.USD","LU2778985437.USD","LU0417516738.SGD","02157","IE00B5MMRT66.SGD","LU2476274720.SGD","LU0348783233.USD","LU0634319403.HKD","LU0417516902.SGD","BK4548","BK1161","BK0239","LU0417516571.SGD","BK1588","BK4139","IE00B543WZ88.USD","159992","BK4526","LU0348784397.USD","BK1191","LU0348827113.USD","BK4585","LU0348767384.USD","ZLAB","BK1574","LU2476274308.USD","LU1720050803.USD","LU0561508036.HKD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.2294},{"period":"3month","weight":-0.3514},{"period":"6month","weight":-0.4765},{"period":"1year","weight":-0.2953},{"period":"ytd","weight":-0.2383}],"compareEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0574},{"period":"6month","weight":0.1423},{"period":"1year","weight":0.1263},{"period":"ytd","weight":0.1677}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再鼎医药有限公司是一家主要从事生物制药的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.10392},{"month":2,"riseRate":0.5,"avgChangeRate":0.014818},{"month":3,"riseRate":0.25,"avgChangeRate":-0.083122},{"month":4,"riseRate":0.375,"avgChangeRate":0.008126},{"month":5,"riseRate":0.5,"avgChangeRate":0.028309},{"month":6,"riseRate":0.5,"avgChangeRate":0.075433},{"month":7,"riseRate":0.5,"avgChangeRate":0.004927},{"month":8,"riseRate":0.625,"avgChangeRate":0.000651},{"month":9,"riseRate":0.375,"avgChangeRate":-0.055585},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.047464},{"month":11,"riseRate":0.555556,"avgChangeRate":0.101421},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.016919}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}